<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Inflamm (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">J Inflamm (Lond)</journal-id><journal-title-group><journal-title>Journal of Inflammation (London, England)</journal-title></journal-title-group><issn pub-type="epub">1476-9255</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5644185</article-id><article-id pub-id-type="publisher-id">169</article-id><article-id pub-id-type="doi">10.1186/s12950-017-0169-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>LPS regulates the expression of glucocorticoid receptor &#x003b1; and &#x003b2; isoforms and induces a selective glucocorticoid resistance in vitro</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Molina</surname><given-names>Maria Luisa</given-names></name><address><email>marialuisamolinac@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guerrero</surname><given-names>Julia</given-names></name><address><email>jguerrero@med.uchile.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cidlowski</surname><given-names>John A.</given-names></name><address><email>cidlows1@niehs.nih.gov</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gatica</surname><given-names>H&#x000e9;ctor</given-names></name><address><email>hgatica@hcuch.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Goecke</surname><given-names>Annelise</given-names></name><address><email>igoecke@hcuch.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 4466</institution-id><institution-id institution-id-type="GRID">grid.443909.3</institution-id><institution>Rheumatology Section, Internal Medicine Department, Clinical Hospital, </institution><institution>University of Chile, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 4466</institution-id><institution-id institution-id-type="GRID">grid.443909.3</institution-id><institution>Physiology and Biophysics Disciplinary Program, ICBM, Faculty of Medicine, </institution><institution>University of Chile, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2110 5790</institution-id><institution-id institution-id-type="GRID">grid.280664.e</institution-id><institution>Department of Health and Human Services, </institution><institution>National Institute of Environmental Health Sciences, National Institutes of Health, </institution></institution-wrap>Research Triangle Park, NC USA </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>14</volume><elocation-id>22</elocation-id><history><date date-type="received"><day>10</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">This study was aimed to evaluate the effect of LPS in glucocorticoid receptor (GR) isoforms expression on different cell lines and PBMC from healthy donors in vitro and glucocorticoid sensitivity of PBMC in vitro.</p></sec><sec><title>Methods</title><p id="Par2">U-2 OS cell lines expressing GR isoforms, different cell lines (CEM, RAJI, K562 and HeLa) or PBMC from healthy donors, were cultured or not with LPS. The expression of GR&#x003b1; and GR&#x003b2; was evaluated by Western blot. Glucocorticoid sensitivity was evaluated in PBMC treated with LPS, testing genes which are transactivated or transrepressed by glucocorticoid. For transactivated genes (MKP1, FKBP5) PBMC were treated with Dexamethasone 100&#x000a0;nM for 6&#x000a0;h. The mRNA expression was measured by RT-PCR. For transrepressed genes (IL-8, GM-CSF), PBMC were cultured in Dexamethasone 100&#x000a0;nM and LPS 10&#x000a0;&#x003bc;g/ml for 6&#x000a0;h and protein expression was measure by ELISA.</p></sec><sec><title>Results</title><p id="Par3">GR isoforms were induced in U-2 OS cells with a greater effect on GR&#x003b1; expression. Both isoforms were also induced in CEM cells with a tendency to a greater effect on GR&#x003b2;. LPS induced only the expression of GR&#x003b1; in Raji and HeLa cells, and in PBMC, with no effect in K562 cells. LPS induced a loss of glucocorticoid inhibitory effect only on the secretion of GM-CSF.</p></sec><sec><title>Conclusion</title><p id="Par4">LPS in vitro differentially modulates the expression of GR isoforms in a cell specific manner. In PBMC from healthy donors LPS induces an approximately two times increase in&#x000a0;the expression of GR&#x003b1; and a loss of the glucocorticoid inhibitory effect on the secretion of GM-CSF, without affecting other glucocorticoid responses evaluated.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12950-017-0169-0) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Lipopolysaccharide</kwd><kwd>Glucocorticoid receptor</kwd><kwd>Glucocorticoid resistance</kwd><kwd>Acute inflammation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002850</institution-id><institution>Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico</institution></institution-wrap></funding-source><award-id>108-0529</award-id><principal-award-recipient><name><surname>Goecke</surname><given-names>Annelise</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par11">Glucocorticoids (GC) have been used as anti-inflammatory and immunosuppressive agents [<xref ref-type="bibr" rid="CR1">1</xref>]. However, the sensitivity to GC actions varies among individuals and even in the same patient at different time points. The mechanisms mediating changes in GC sensitivity are not completely understood [<xref ref-type="bibr" rid="CR2">2</xref>]. A better understanding of the factors that could influence the cell response to GC is relevant to adapt GC therapy to different requirements in patients suffering autoimmune/inflammatory diseases.</p><p id="Par12">The GC actions are mediated through the activation of intracellular glucocorticoid receptors (GR)<bold><italic>.</italic></bold> The genomic structure of the single GR gene described in humans consists of 9 exons. Alternative splicing of exon 9 (exon 9&#x003b1; or 9&#x003b2;) results in the synthesis of 2 homologous mRNAs and protein isoforms, termed GR&#x003b1; and GR&#x003b2; [<xref ref-type="bibr" rid="CR3">3</xref>]. After GC binds GR&#x003b1;, it binds as a homodimer to DNA, regulating the expression of the linked gene. GR&#x003b1; can also modulate gene expression by interacting with other transcription factors such as AP-1 and NF-&#x003ba;B, exerting most of the anti-inflammatory actions by this mechanism [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. GR&#x003b2; differs from GR&#x003b1; only in its carboxi-terminus sequence. This difference renders to GR&#x003b2; a role as a dominant negative inhibitor of GR&#x003b1; activity. Therefore, a relative over-expression of the GR&#x003b2; isoform could play a role in the regulation of target cell sensitivity to GC [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Indeed, studies have demonstrated that GR&#x003b2; expression is elevated in patients with chronic inflammatory diseases associated with GC resistance e.g. asthma, inflammatory bowel disease and nasal polyps [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par13">It has long been proposed that infectious episodes could trigger relapses in autoimmune diseases [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Our group has demonstrated a transient increased expression of GR&#x003b2; in peripheral blood mononuclear cells (PBMC) from septic patients. We also showed that septic serum influence GC sensitivity, favoring the expression of GR&#x003b2; in association with a GC resistant state [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Number of factors, present in serum from septic patients, such as cytokines, bacterial products and GC, either by themselves or in combination could be responsible for these effects.</p><p id="Par14">Webster et al. [<xref ref-type="bibr" rid="CR19">19</xref>] showed that TNF-&#x003b1; and IL-1 induced the expression of both GR isoforms mRNA in HeLa and CEM-C7 cell lines, but the increase of the expression of GR&#x003b2; was greater than GR&#x003b1; in those conditions. Other proinflammatory cytokines has also been reported to increase the expression of GR&#x003b2; in vitro, such as IL-7, IL-18, and the combination of IL-2 and IL-4 in PBMC, and IL-8 in human neutrophils [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Interestingly, these cytokine treatments resulted in decreased sensitivity to GC in these cell types [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Also, bacterial superantigens and bacterial toxins have been reported to increase the expression of GR&#x003b2; [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par15">Septic serum also contains fragments of bacteria which are recognized by innate immune system [<xref ref-type="bibr" rid="CR24">24</xref>]. In our study, serum samples were obtained mostly from patients where a gram-negative infection was either suspected, due to the primary septic source or demonstrated by culture [<xref ref-type="bibr" rid="CR18">18</xref>]. TLR4 recognizes lipopolysaccharides (LPS) present in gram-negative bacteria leading to the subsequent induction of the initial inflammatory response [<xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, the influence of septic serum on GR and GC cell sensitivity in our study could have been the consequence of the activation of TLR4 by LPS.</p><p id="Par16">It is known that GC secreted endogenously by the adrenal gland restrict the responses to TLR [<xref ref-type="bibr" rid="CR26">26</xref>]. Multiple mechanisms have been described for the GC interference with TLRs signaling [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However, if TLR activation influences GR expression or GC sensitivity, has been scarcely studied. Indirect evidence of an effect of TLR activation on GR isoforms expression comes from two studies were an up regulation of GR&#x003b2; expression was reported in vivo after the exposure to TLR4 agonist. One, in a septic animal model induced by LPS injection [<xref ref-type="bibr" rid="CR29">29</xref>], and the other studying children with respiratory syncytial virus (RSV) infection, another known agonist of TLR4 [<xref ref-type="bibr" rid="CR30">30</xref>]. However, it should be noted that after the induction of sepsis, and in children with RSV infection, changes in metabolic parameters, as well as cytokines, toxins and stress hormones levels are expected. Therefore, it is unclear the cause of GR isoforms modulation in both situations. The effect of LPS has been tested in vitro in bone marrow-derived macrophages and nasal mucosa fibroblasts with contradictory results, but it has not been evaluated on PBMC or lymphocytes in vitro [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par17">In this report, we evaluated the effect of LPS, a TLR4 agonist, on GR&#x003b1; and GR&#x003b2; expression in different cell lines and PBMC from healthy donors in culture. We also explore the effect of LPS on GC cell sensitivity in vitro.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Cell culture and transfection</title><p id="Par18">Human cell lines (CEM, K562, Raji and HeLa) were obtained from American Type Culture Collection, U-2 OS from Dr. Marcel Shaaf, and PBMC from healthy donors. CEM, K562, Raji cells and PBMC were grown in RPMI-1640 medium (GIBCO), supplemented with 10% fetal calf serum (FCS), 4&#x000a0;mM L-glutamine,100&#x000a0;U/ml penicillin, 100 &#x003bc;g/ml streptomycin at 37 &#x000b0;C in a 5% CO<sub>2</sub> humidified atmosphere. HeLa and U-2 OS cells were grown in DMEM-F12 medium (Invitrogen Life Technologies) containing 10% FCS, glutamine, penicillin and streptomycin as described above.</p><p id="Par19">Cell viability was &#x0003e;95%, determined by trypan blue exclusion staining, in cultures in the presence or not of LPS.</p><p id="Par20">U-2 OS cell lines stably expressing human GR&#x003b1; or GR&#x003b2; isoform were generated as previously described [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec4"><title>Mononuclear cell extraction</title><p id="Par21">Peripheral venous blood samples (30&#x000a0;ml) from healthy volunteers were collected and PBMC were isolated by density gradient centrifugation (Ficoll-Paque Plus, Amersham Bioscience). Written informed consent was previously obtained from all volunteers, according to the Declaration of Helsinki.</p></sec><sec id="Sec5"><title>Stimulation with LPS</title><p id="Par22">U-2 OS, CEM, K562, Raji, HeLa cells and PBMC (2&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> cells/ml) were cultured with LPS from <italic>E.coli</italic> serotype O111:B4 (Sigma-Aldrich) at 0.1, 1, 10 &#x003bc;g/ml; or only the vehicle as control, for 24&#x000a0;h.</p></sec><sec id="Sec6"><title>GC sensitivity assay</title><p id="Par23">PBMC treated previously with or without LPS for 24&#x000a0;h were washed twice with PBS 1X and then GC sensitivity was evaluated by measuring: 1) Dexamethasone (DEX) induction of FKPB5 and MKP1 mRNA expression. Briefly, PBMC were cultured in the presence or absence of DEX 100&#x000a0;nM for 6&#x000a0;h, then FKPB5 and MKP1 mRNA expression was evaluated by qPCR. 2) DEX inhibition of LPS induced IL-8 and GM-CSF release by ELISA. Briefly PBMC were re-stimulated with 10 &#x003bc;g/ml of LPS for 6&#x000a0;h in presence or absence of DEX 100&#x000a0;nM. After incubation, cells were centrifuged and supernatant were collected and stored until the ELISA assay.</p></sec><sec id="Sec7"><title>Western blot analysis</title><p id="Par24">Cells were harvested and lysed using RIPA buffer (50&#x000a0;mM Tris pH&#x000a0;8.0, 150&#x000a0;mM NaCl, 1% Tween 20, 0.5% SDS) containing protease inhibitors (0.1&#x000a0;mM phenylmetthylsulfonyl fluoride, 1 &#x003bc;g/ml aprotinin, 1 &#x003bc;M pepstatin, 1 &#x003bc;M leupeptin). Proteins (50&#x003bc;g) were resolved by electrophoresis through 10% polyacrylamide gels and transferred to nitrocellulose membranes as previously described [<xref ref-type="bibr" rid="CR18">18</xref>]. Membranes were blocked in PBS 1X containing 10% nonfat dry milk and 0,1% Tween 20, and incubated overnight at 4&#x000b0;C with a purified polyclonal rabbit anti-hGR antiserum (dilution 1:1000 to 1:2000) [<xref ref-type="bibr" rid="CR34">34</xref>], specific polyclonal rabbit anti-GR&#x003b1; antibodies (dilution 1:200) (GR P-20: sc1002; Santa Cruz Biotecnology Inc., Santa Cruz, CA, USA), or specific polyclonal rabbit anti-GR&#x003b2; antibodies (dilution 1:500) (PA3&#x02013;514; Affinity BioReagents, Golden, CO, USA.); and 1&#x000a0;h at room temperature with mouse monoclonal anti &#x003b2;-actin (dilution 1:40,000) (Santa Cruz Biotecnology, Inc). Secondary biotinilated polyclonal antibodies against rabbit or mouse IgG (DAKO) were used for GR and &#x003b2;-actin detection, respectively. Films were densitometrically analyzed using Image J (Scion Corp.) and normalized to &#x003b2;-actin as loading control.</p></sec><sec id="Sec8"><title>Quantitative real-time PCR analysis</title><p id="Par25">Total RNA was isolated using Trizol<sup>&#x000ae;</sup> Reagent (Invitrogen) according to the manufacturer&#x02019;s instructions. RNA concentration was determined by spectrophotometry and integrity of RNA by agarose gel electrophoresis. One &#x003bc;g of RNA was reverse transcribed using ImProm-II&#x02122; Reverse Transcription System (Promega). PCR analysis was performed in triplicate for each experiment with Brilliant SYBR Green in the Mx3000P&#x000ae; real-time PCR system (Stratagene, La Jolla, CA). The primers used for RT-PCR were MKP1: 5&#x02032;-GGTTCTTCTAGGAGTAGACA-3&#x02032; (upstream) and 5&#x02032;-GTACATCAAGTCCATCTGAC-3&#x02032; (downstream); FKPB5: 5&#x02032;-TTGAGGAGGGGCCGAGTT-3&#x02032; (upstream) and 5&#x02032;-AAAAGGCCAAGGAGCACAAC-3&#x02032; (downstream); h18S (housekeeping): 5&#x02032;-GATATGCTCATGTGGTGTTG-3&#x02032; (upstream) and 5&#x02032;-AATCTTCTTCAGTCGCTCCA-3&#x02032; (downstream). Relative mRNA levels for each sample were quantified using the threshold cycle (C<sub>t</sub>) approach and normalized with respect to h18S RNA.</p></sec><sec id="Sec9"><title>IL-8 and GM-CSF release quantification</title><p id="Par26">Immunoreactive IL-8 and GM-CSF were determined on the supernatants of PBMC from the GC sensitivity assay by ELISA according to the manufacturer&#x02019;s instructions (Pierce Biotechnology, Inc.). Data are presented as the average of triplicate results. The lower limit of detection was 2&#x000a0;pg/ml for both assays.</p></sec><sec id="Sec10"><title>Statistic analysis</title><p id="Par27">All data are presented as medians with interquartile range and range of at least three independent experiments. Data were analyzed using Student&#x02019;s t test for normally distributed data and the Mann-Whitney test for nonparametric data, considering a <italic>p</italic>-<italic>value</italic>&#x000a0;&#x0003c;&#x000a0;0.05 statistically significant.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>LPS regulates the expression of GR&#x003b1; and GR&#x003b2; isoforms in U-2 OS transfected cells</title><p id="Par28">Western blot analysis of total proteins from human osteosarcoma cell line lacking endogenous GR (parental U-OFF cells, line 1), transfected with GR&#x003b1; (U-2 OS alpha, line 2) or GR&#x003b2; (U-2 OS beta, line 3) using different antiGR antibodies is showed in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>. When an antibody common to both GR isoforms was used, a protein of ~ 90&#x02013;95&#x000a0;kDa was detected in cells stably expressing GR&#x003b1; or GR&#x003b2; isoform, but not in parental U-OFF cells. When an antibody specific for GR&#x003b2; was used, a protein of ~ 90&#x000a0;kDa was identified only in U-2 OS beta cells.<fig id="Fig1"><label>Fig. 1</label><caption><p>LPS regulates the expression of GR&#x003b1; and GR&#x003b2; isoforms in U-2 OS transfected cells. <bold>a</bold>. Western blot of total proteins of parental U-OFF cells (line 1), U-2 OS alpha cells (line 2) and U-2 OS beta cells (line 3) are shown. On the left panel, a common antibody to GR was used and on the right panel a specific GR&#x003b2; antibody was used. U2-OS alpha (<bold>b</bold>) and US-OS beta (<bold>c</bold>) cells were stimulated with LPS for 24&#x000a0;h. The expression of GR&#x003b1; and GR&#x003b2; was determined by Western blot. The median values of three different experiments, plotted as values relative to control are shown. * <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and ** <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p></caption><graphic xlink:href="12950_2017_169_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par29">To evaluate whether LPS stimulation modified GR&#x003b1; or GR&#x003b2; protein expression in these cells, U-2 OS alpha or U-2 OS beta cells were cultured with different concentrations of LPS (0.1, 1 or 10 &#x003bc;g/ml). After 24&#x000a0;h the expression of GR&#x003b1; and GR&#x003b2; was evaluated by Western blot with specific antibodies for each isoform. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref> shows that all concentrations of LPS induced at least a significant 6 fold increased expression of GR&#x003b1; (median 6.23, range 5.99&#x02013;6.41 for LPS 0.1 &#x003bc;g/ml, median 6.04, range 5.76&#x02013;6.18 for LPS 1 &#x003bc;g/ml, median 6.04, range 5.96&#x02013;6.23 for LPS 10 &#x003bc;g/ml; <italic>p</italic>&#x000a0;=&#x000a0;0.002). LPS at low concentrations, but not LPS 10 &#x003bc;g/ml, induced a significant increase of smaller magnitude in GR&#x003b2; protein expression (LPS 0.1&#x003bc;g/ml: median 1.25, range 1.23&#x02013;1.72; LPS 1&#x003bc;g/ml: median 1.23, range 1.15&#x02013;1.27; <italic>p</italic>&#x000a0;=&#x000a0;0.002) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>).</p></sec><sec id="Sec13"><title>LPS regulates the expression of GR&#x003b1; and GR&#x003b2; isoforms in immune and epithelial cell lines</title><p id="Par30">To assess whether LPS modulates the expression of GR isoforms in cells constitutively expressing this receptor, a monocytic cell line (K562) and two human cell lines of lymphoid origin (CEM and Raji) were used. These cells were treated or not with 10&#x000a0;ng/ml or 10 &#x003bc;g/ml of LPS for 24&#x000a0;h. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, LPS treatment induced a different response in the human immune cells studied. In K562 there was no change in the expression of GR isoforms at 10&#x000a0;ng/ml and 10 &#x003bc;g/ml of LPS (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). In Raji cells there was a significant increase in only GR&#x003b1; expression at both concentrations used (LPS 10&#x000a0;ng/ml: median 1.57, range 1.29&#x02013;1.66, <italic>p</italic>&#x000a0;=&#x000a0;0.01; LPS 10 &#x003bc;g/ml: median 1.98, range 1.91&#x02013;2.55, <italic>p</italic>&#x000a0;=&#x000a0;0.03) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). In CEM cells there was an increase in the expression of both GR isoforms, being only statistically significant at LPS 10 &#x003bc;g/ml (GR&#x003b1;: median 1.18, range 0.99&#x02013;1.63, <italic>p</italic>&#x000a0;=&#x000a0;0.002; GR&#x003b2;: median 1.38, range 1.10&#x02013;1.55, <italic>p</italic>&#x000a0;=&#x000a0;0.002) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>LPS regulates the expression of GR&#x003b1; and GR&#x003b2; isoforms in immune cell lines. K562 (<bold>a</bold>), Raji (<bold>b</bold>), CEM (<bold>c</bold>) cells were cultured with LPS for 24&#x000a0;h. The expression of GR&#x003b1; and GR&#x003b2; was determined by Western blot. The median values of three different experiments, plotted as values relative to control are shown. * <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and ** <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p></caption><graphic xlink:href="12950_2017_169_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par31">In HeLa cells, an epithelial cell line, there was a significant increase only in GR&#x003b1; expression (median 1.86, range 1.02&#x02013;2.37, <italic>p</italic>&#x000a0;=&#x000a0;0.002), with no change in GR&#x003b2; expression when treated with 10 &#x003bc;g/ml of LPS for 24&#x000a0;h (Additional file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>).</p></sec><sec id="Sec14"><title>LPS regulates the expression of GR&#x003b1; in PBMC from healthy individuals</title><p id="Par32">We examined whether LPS modulates de expression of GR proteins isoforms in PBMC from healthy individuals. As shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>, LPS 10 &#x003bc;g/ml treatment significantly increased GR&#x003b1; protein expression (median 1.95, range 1.04&#x02013;4.35, <italic>p</italic>&#x000a0;=&#x000a0;0.007), while GR&#x003b2; protein expression was not modified. When PBMC were stimulated with LPS 10&#x000a0;ng/ml, a similar result was obtained as mentioned before (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>LPS regulates the expression of GR&#x003b1; in PBMC from healthy individuals. PBMC from healthy individuals were cultured with LPS for 24&#x000a0;h. The expression of GR&#x003b1; and GR&#x003b2; was determined by Western blot. <bold>a</bold> The median values of three different experiments, plotted as values relative to control are shown. * <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and ** <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01. <bold>b</bold> Western blot of total proteins of PBMC stimulated at different concentrations of LPS are shown</p></caption><graphic xlink:href="12950_2017_169_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec15"><title>LPS modifies DEX sensitivity depending on the gene studied</title><p id="Par33">To assess whether LPS modify DEX sensitivity in PBMC from healthy individuals, we evaluated genes known to be transactivated o transrepressed by GC. The expression of two genes known to be up regulated by DEX, MKP-1 and FKPB5 were first tested. PBMC were stimulated or not with LPS 10 &#x003bc;g/ml for 24&#x000a0;h, followed by 6&#x000a0;h of DEX 100&#x000a0;nM. DEX induced the expression of MKP-1 and FKPB5 mRNA in PBMC previously treated or not with LPS, but LPS pretreatment did not modify the inducing effect of DEX on MKP-1 (Control 4.82&#x000b1;1.1 vs LPS 3.76&#x000b1;1.6 fold increase, <italic>p</italic>&#x000a0;=&#x000a0;0.66) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>) and FKPB5 (Control 16.69&#x000b1;7.6 vs LPS 15.62&#x000b1;8.5 fold increase, <italic>p</italic>&#x000a0;=&#x000a0;0.95) mRNA expression (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>GC Sensitivity Assay in Transactivated Genes. PBMC from healthy individuals were cultured for 24&#x000a0;h with or without LPS, follow for Dex 100&#x000a0;nM for 6&#x000a0;h. MKP1 (<bold>a</bold>) and FKPB5 (<bold>b</bold>) mRNA expression was analyzed by RT-PCR. The median values of three different experiments, plotted as values relative to control, are shown. * <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and ** <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p></caption><graphic xlink:href="12950_2017_169_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par34">To evaluate LPS effect in DEX sensitivity in genes known to be down-regulated by GC, we test DEX capacity to inhibit LPS induced IL-8 and GM-CSF protein expression. PBMC from healthy individuals were first stimulated or not with LPS 10 &#x003bc;g/ml for 24&#x000a0;h and then re-stimulated for 6&#x000a0;h with LPS 10 &#x003bc;g/ml and DEX 100&#x000a0;nM. As show in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, DEX inhibited LPS induced expression of GM-CSF when PBMC were not pretreated with LPS (0.64 &#x000b1;0.18 fold increase respect to control, <italic>p</italic>&#x000a0;=&#x000a0;0.0022), while DEX in PBMC pretreated with LPS did not inhibited LPS induced expression of this cytokine (0.92&#x000b1;0.27 fold increase respect to control, <italic>p</italic>&#x000a0;=&#x000a0;0.36) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). The inhibitory effect did not change in PBMC pretreated with LPS when IL-8 was evaluated (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>GC Sensitivity Assay in transrepressed genes. PBMC from healthy individuals were cultured for 24&#x000a0;h with or without LPS, follow by DEX 100&#x000a0;nM and LPS 10&#x000a0;&#x003bc;g/ml for 6&#x000a0;h. IL-8 (<bold>a</bold>) and GM-CSF (<bold>b</bold>) content in the culture media was measure by ELISA. The median values of three different experiments, plotted as values relative to control are shown. * <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and ** <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p></caption><graphic xlink:href="12950_2017_169_Fig5_HTML" id="MO5"/></fig>
</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par35">Infectious episodes in patients with autoimmune diseases have been always a challenge. Not only because these patients are prone to more severe infections since they commonly are receiving immunosuppressive drugs such as GC, but also because frequently a flare is triggered. Since GC are important in the treatment of autoimmune diseases and also are a key factor in the response to infections, it is important to understand how an infection can influence the cell response to GCs.</p><p id="Par36">This study has shown that LPS, present in Gam-negative bacteria cell wall, is able to differentially regulate the expression of GR&#x003b1; and GR&#x003b2; in different cell lines and PBMC from healthy donors in culture. LPS induced both, GR&#x003b1; and GR&#x003b2; in transfected cells (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref> and <xref rid="Fig1" ref-type="fig">c</xref>), but with an approximately four times greater effect on GR&#x003b1; expression. Some other groups have evaluated the effect of LPS on the expression of GR. Haim et al. showed that LPS on bone marrow-derived macrophages induced preferentially the expression of GR&#x003b2;, resulting in a partial GC resistance [<xref ref-type="bibr" rid="CR31">31</xref>]. However, Fern&#x000e1;ndez-Bertol&#x000ed;n et al., have shown that LPS 10 &#x003bc;g/ml did not modify the expression of GR on nasal mucosa fibroblasts, but it did induce a GC resistance for some but not all GC actions tested [<xref ref-type="bibr" rid="CR32">32</xref>]. We therefore evaluated the effect of LPS on different cell lines relevant in the immune system. As is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, LPS in CEM cells (T cell line) induced both, GR&#x003b1; and GR&#x003b2; isoforms expression at the same concentrations used by Fernandez-Bertolin et al. [<xref ref-type="bibr" rid="CR32">32</xref>], with a tendency to a greater effect on GR&#x003b2;, similar to the results of Haim et al. in macrophages. However LPS induced only the expression of GR&#x003b1; in Raji (B cell line) and HeLa (epithelial cell line) cells (Additional file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>), with no effect in the expression of either isoforms in K562 cells. Therefore, our results and what has been reported previously demonstrate that LPS can affect the expression of the GR isoforms, but this is a cell type specific response.</p><p id="Par37">Since in normal circumstances T cells, B cells and monocytes will coexist when exposed to LPS, influencing each other, we decided to evaluate the effect of LPS on PBMC in vitro. Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows that in these conditions there was an almost two time&#x000a0;increase in GR&#x003b1; expression with no change in GR&#x003b2;. This effect is opposite to the effect of serum from septic patients, which induced preferentially GR&#x003b2; expression on PBMC from healthy donors [<xref ref-type="bibr" rid="CR19">19</xref>]. There are several possible explanations for this apparent contradiction. For instance, LPS is just one of the components of the serum of patients with septic states. In an inflammatory process induced by LPS there are many mediators such as cytokines, chemokines, lipid mediators, and reactive oxygen species among others that participate in the inflammatory process [<xref ref-type="bibr" rid="CR35">35</xref>]. Any of these components could modulate the expression of GR isoforms, and even depending on the concentration balance of these mediators, different responses could be elicited.</p><p id="Par38">The GR&#x003b1; commonly has been described as the active GR isoform which mediates most of known GC actions, while GR&#x003b2; can exert a negative dominant action over GR&#x003b1;. Therefore, we expected that LPS would induced an increase sensitivity to GC actions on PBMC. Surprisingly our results showed that LPS treatment induced a loss of GC inhibitory effect on the production of GM-CSF. This resistance to GC effects was not generalized, since the inhibitory effect on the production of IL-8 or the induction of MKP-1 and FKPB-5 were maintained (Figs.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> and&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The effects of GC even when mediated by GR, are not only dependent on the ratio of expression of GR&#x003b1; and &#x003b2;. They can also be altered by nuclear translocation, changes in GR affinity, phosphorylation, among others [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Therefore, it is possible that one or several of this factors could be involved in the GC loss of inhibition of GM-CSF induced by LPS. Indeed, in NM fibroblast, Fern&#x000e1;ndez-Bertolin et al. showed that LPS 10 &#x003bc;g/ml treatment lead to a reduced dexamethasone-induced GR&#x003b1; nuclear translocation and a decreased GILZ expression without changing the GR&#x003b1;/GR&#x003b2; expression and maintaining dexamethasone&#x02019;s induction effect on MKP-1 and GILZ expression. Therefore, they also showed a GC resistant state limited to some but not all GC effects which was not associated to a change on GR expression [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par39">It is also interesting that Armstrong et al., showed that even when most cytokines maintain a normal sensitivity to GC actions in macrophages from COPD patients a GC resistance was demonstrated for GM-CSF [<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec17"><title>Conclusions</title><p id="Par40">In summary our study showed that LPS in vitro modulates the expression of GR&#x003b1; and GR&#x003b2; isoforms in a cell specific manner. In PBMC from healthy donor LPS induces the expression of GR&#x003b1; with no change of expression of GR&#x003b2;. It also induces a loss of GC inhibitory effect on the secretion of GM-CSF without affecting GC induction of MKP1 or FKBP5.</p><p id="Par41">From our results as well as others, it is important to note that GCs effects can be modulated in a cell and effect specific manner. Therefore, it is not possible when a particular change of GC effects is observed under certain condition, to extrapolate those findings to other GC actions.</p></sec></body><back><app-group><app id="App1"><sec id="Sec18"><title>Additional file</title><p id="Par48">
<media position="anchor" xlink:href="12950_2017_169_MOESM1_ESM.tiff" id="MOESM1"><label>Additional file 1:</label><caption><p>LPS regulates the expression of GR&#x003b1; and GR&#x003b2; isoforms in a epithelial cell line. HeLa cells were cultured with LPS for 24&#x000a0;h. The expression of GR&#x003b1; and GR&#x003b2; was determined by Western blot. The median values of three different experiments, plotted as values relative to control are shown. * <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and ** <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01. (TIFF 128&#x000a0;kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviaitons</title><def-list><def-item><term>DEX</term><def><p id="Par5">Dexamethasone</p></def></def-item><def-item><term>GC</term><def><p id="Par6">Glucocorticoids</p></def></def-item><def-item><term>GR</term><def><p id="Par7">Glucocorticoid receptor</p></def></def-item><def-item><term>LPS</term><def><p id="Par8">Lipopolysaccharides</p></def></def-item><def-item><term>PBMC</term><def><p id="Par9">Peripheral blood mononuclear cells</p></def></def-item><def-item><term>RSV</term><def><p id="Par10">Respiratory syncytial virus</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s12950-017-0169-0) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Ms. Rosario Flores for her technical assistance.</p><sec id="FPar1"><title>Funding</title><p id="Par42">This work was supported by FONDECYT 108&#x02013;0529.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par43">Please contact the corresponding author for data request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MLM, JG and AG equally contributed to the design of the study and the writing of the manuscript. MLM performed in vitro experiments with PBMC and sensitivity tests to glucocorticoid and JG performed in vitro experiments with naive and transfected cell lines. AG and JC contributed to the revision of the article and its intellectual content. HG contributed to the elaboration of the statistical analysis and interpretation of data. All authors have read and aproved the final manuscript before submission.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par44">The study was approved by Fondecyt-Conicyt Bioethics Advisory Committee on April 4th, 2008.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par45">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par46">The authors declare that they have not competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par47">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttgereit</surname><given-names>F</given-names></name><name><surname>Straub</surname><given-names>RH</given-names></name><name><surname>Wehking</surname><given-names>M</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name></person-group><article-title>Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>3408</fpage><lpage>3417</lpage><pub-id pub-id-type="doi">10.1002/art.20583</pub-id><?supplied-pmid 15529366?><pub-id pub-id-type="pmid">15529366</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>KL</given-names></name><name><surname>Lu</surname><given-names>NZ</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>Molecular mechanisms regulating glucocorticoid sensitivity and resistance</article-title><source>Mol Cell Endocrinol</source><year>2009</year><volume>300</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2008.10.001</pub-id><?supplied-pmid 19000736?><pub-id pub-id-type="pmid">19000736</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>SM</given-names></name><name><surname>Weinberger</surname><given-names>C</given-names></name><name><surname>Ong</surname><given-names>ES</given-names></name><name><surname>Cerelli</surname><given-names>G</given-names></name><name><surname>Oro</surname><given-names>A</given-names></name><name><surname>Lebo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Primary structure and expression of a functional human glucocorticoid receptor cDNA</article-title><source>Nature</source><year>1985</year><volume>318</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/318635a0</pub-id><?supplied-pmid 2867473?><pub-id pub-id-type="pmid">2867473</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujols</surname><given-names>L</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Torrego</surname><given-names>A</given-names></name><name><surname>Picado</surname><given-names>C</given-names></name></person-group><article-title>Glucocorticoid receptors in human airways</article-title><source>Allergy</source><year>2004</year><volume>59</volume><fpage>1042</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2004.00635.x</pub-id><?supplied-pmid 15355461?><pub-id pub-id-type="pmid">15355461</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bosscher</surname><given-names>K</given-names></name><name><surname>Vanden Berghe</surname><given-names>W</given-names></name><name><surname>Haegeman</surname><given-names>G</given-names></name></person-group><article-title>The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein &#x02212;1: molecular mechanisms of gene repression</article-title><source>Endocr Rev</source><year>2003</year><volume>24</volume><fpage>488</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1210/er.2002-0006</pub-id><?supplied-pmid 12920152?><pub-id pub-id-type="pmid">12920152</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>DY</given-names></name><name><surname>Bloom</surname><given-names>JW</given-names></name></person-group><article-title>Update on glucocorticoid action and resistance</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><fpage>3</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S0091-6749(03)70087-6</pub-id><?supplied-pmid 12532089?><pub-id pub-id-type="pmid">12532089</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busillo</surname><given-names>JM</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore</article-title><source>Trends Endocrinol Metab</source><year>2013</year><volume>24</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2012.11.005</pub-id><?supplied-pmid 23312823?><pub-id pub-id-type="pmid">23312823</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname><given-names>RH</given-names></name><name><surname>Jewell</surname><given-names>CM</given-names></name><name><surname>Yudt</surname><given-names>MR</given-names></name><name><surname>Bofetiado</surname><given-names>D</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>27857</fpage><lpage>27866</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.39.27857</pub-id><?supplied-pmid 10488132?><pub-id pub-id-type="pmid">10488132</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yudt</surname><given-names>MR</given-names></name><name><surname>Jewell</surname><given-names>CM</given-names></name><name><surname>Bienstock</surname><given-names>RJ</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>Molecular origins for the dominant negative function of human glucocorticoid receptor beta</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><fpage>4319</fpage><lpage>4330</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.12.4319-4330.2003</pub-id><?supplied-pmid 12773573?><pub-id pub-id-type="pmid">12773573</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamid</surname><given-names>QA</given-names></name><name><surname>Wenzel</surname><given-names>SE</given-names></name><name><surname>Hauk</surname><given-names>PJ</given-names></name><name><surname>Tsicopoulos</surname><given-names>A</given-names></name><name><surname>Wallaert</surname><given-names>B</given-names></name><name><surname>Lafitte</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>1600</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.159.5.9804131</pub-id><?supplied-pmid 10228133?><pub-id pub-id-type="pmid">10228133</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goleva</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>LB</given-names></name><name><surname>Eves</surname><given-names>PT</given-names></name><name><surname>Strand</surname><given-names>MJ</given-names></name><name><surname>Martin</surname><given-names>RJ</given-names></name><name><surname>Leung</surname><given-names>DY</given-names></name></person-group><article-title>Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>607</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1164/rccm.200507-1046OC</pub-id><?supplied-pmid 16387802?><pub-id pub-id-type="pmid">16387802</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Orii</surname><given-names>F</given-names></name><name><surname>Ayabe</surname><given-names>T</given-names></name><name><surname>Imai</surname><given-names>S</given-names></name><name><surname>Ashida</surname><given-names>T</given-names></name><name><surname>Obara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis</article-title><source>Gastroenterology</source><year>2000</year><volume>118</volume><fpage>859</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(00)70172-7</pub-id><?supplied-pmid 10784585?><pub-id pub-id-type="pmid">10784585</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orii</surname><given-names>F</given-names></name><name><surname>Ashida</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Maemoto</surname><given-names>A</given-names></name><name><surname>Fujiki</surname><given-names>T</given-names></name><name><surname>Ayabe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Quantitative analysis for human glucocorticoid receptor alpha/beta mRNA in IBD</article-title><source>Biochem Biophys Res Commun</source><year>2002</year><volume>296</volume><fpage>1286</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(02)02030-2</pub-id><?supplied-pmid 12207914?><pub-id pub-id-type="pmid">12207914</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilos</surname><given-names>DL</given-names></name><name><surname>Leung</surname><given-names>DY</given-names></name><name><surname>Muro</surname><given-names>S</given-names></name><name><surname>Kahn</surname><given-names>AM</given-names></name><name><surname>Hamilos</surname><given-names>SS</given-names></name><name><surname>Thawley</surname><given-names>SE</given-names></name><etal/></person-group><article-title>GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>108</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1067/mai.2001.116428</pub-id><?supplied-pmid 11447383?><pub-id pub-id-type="pmid">11447383</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samarkos</surname><given-names>M</given-names></name><name><surname>Vaiopoulos</surname><given-names>G</given-names></name></person-group><article-title>The role of infections in the pathogenesis of autoimmune diseases</article-title><source>Curr Drugs Targets Inflamm Allergy</source><year>2005</year><volume>4</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.2174/1568010053622821</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group><article-title>Infections, rheumatism and autoimmunity: The conflicting relationship between humans and their environment</article-title><source>Autoimmun Rev</source><year>2008</year><volume>8</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2008.07.014</pub-id><?supplied-pmid 18707029?><pub-id pub-id-type="pmid">18707029</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goecke</surname><given-names>A</given-names></name><name><surname>Guerrero</surname><given-names>J</given-names></name></person-group><article-title>Glucocorticoid receptor beta in acute and chronic inflammatory conditions: clinical implications</article-title><source>Immunobiology</source><year>2006</year><volume>211</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2005.11.002</pub-id><?supplied-pmid 16446173?><pub-id pub-id-type="pmid">16446173</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero</surname><given-names>J</given-names></name><name><surname>Gatica</surname><given-names>HA</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Estay</surname><given-names>R</given-names></name><name><surname>Goecke</surname><given-names>IA</given-names></name></person-group><article-title>Septic serum induces glucocorticoid resistance and modifies the expression of glucocorticoid isoforms receptors: a prospective cohort study and in vitro experimental assay</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><fpage>R107</fpage><pub-id pub-id-type="doi">10.1186/cc12774</pub-id><?supplied-pmid 23759144?><pub-id pub-id-type="pmid">23759144</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>JC</given-names></name><name><surname>Oakley</surname><given-names>RH</given-names></name><name><surname>Jewell</surname><given-names>CM</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>6865</fpage><lpage>6870</lpage><pub-id pub-id-type="doi">10.1073/pnas.121455098</pub-id><?supplied-pmid 11381138?><pub-id pub-id-type="pmid">11381138</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>DY</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name><name><surname>Vottero</surname><given-names>A</given-names></name><name><surname>Szefler</surname><given-names>SJ</given-names></name><name><surname>Surs</surname><given-names>W</given-names></name><name><surname>Minshall</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta</article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><fpage>1567</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1084/jem.186.9.1567</pub-id><?supplied-pmid 9348314?><pub-id pub-id-type="pmid">9348314</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strickland</surname><given-names>I</given-names></name><name><surname>Kisich</surname><given-names>K</given-names></name><name><surname>Hauk</surname><given-names>PJ</given-names></name><name><surname>Vottero</surname><given-names>A</given-names></name><name><surname>Chrousos</surname><given-names>GP</given-names></name><name><surname>Klemm</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1084/jem.193.5.585</pub-id><?supplied-pmid 11238589?><pub-id pub-id-type="pmid">11238589</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fakhri</surname><given-names>S</given-names></name><name><surname>Tulic</surname><given-names>M</given-names></name><name><surname>Christodoulopoulos</surname><given-names>P</given-names></name><name><surname>Fukakusa</surname><given-names>M</given-names></name><name><surname>Frenkiel</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>DY</given-names></name><etal/></person-group><article-title>Microbial superantigens induce glucocorticoid receptor beta and steroid resistance in a nasal explant model</article-title><source>Laryngoscope</source><year>2004</year><volume>114</volume><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1097/00005537-200405000-00019</pub-id><?supplied-pmid 15126750?><pub-id pub-id-type="pmid">15126750</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fakhri</surname><given-names>S</given-names></name><name><surname>Christodoulopoulos</surname><given-names>P</given-names></name><name><surname>Tulic</surname><given-names>M</given-names></name><name><surname>Fukakusa</surname><given-names>M</given-names></name><name><surname>Frenkiel</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>DY</given-names></name><etal/></person-group><article-title>Role of microbial toxins in the induction of glucocorticoid receptor beta expression in an explant model of rhinosinusitis</article-title><source>J Otolaryngol</source><year>2003</year><volume>32</volume><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.2310/7070.2003.13994</pub-id><?supplied-pmid 14967085?><pub-id pub-id-type="pmid">14967085</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Amersfoort</surname><given-names>ES</given-names></name><name><surname>Van Berkel</surname><given-names>TJ</given-names></name><name><surname>Kuiper</surname><given-names>J</given-names></name></person-group><article-title>Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock</article-title><source>Clin Microbiol Rev</source><year>2003</year><volume>16</volume><fpage>379</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1128/CMR.16.3.379-414.2003</pub-id><?supplied-pmid 12857774?><pub-id pub-id-type="pmid">12857774</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poltorak</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Smirnova</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>MY</given-names></name><name><surname>Van Huffel</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><etal/></person-group><article-title>Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>2085</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1126/science.282.5396.2085</pub-id><?supplied-pmid 9851930?><pub-id pub-id-type="pmid">9851930</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrousos</surname><given-names>GP</given-names></name></person-group><article-title>The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>1351</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1056/NEJM199505183322008</pub-id><?supplied-pmid 7715646?><pub-id pub-id-type="pmid">7715646</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>SM</given-names></name><name><surname>Lawrence</surname><given-names>T</given-names></name><name><surname>Kleiman</surname><given-names>A</given-names></name><name><surname>Warden</surname><given-names>P</given-names></name><name><surname>Medghalchi</surname><given-names>M</given-names></name><name><surname>Tuckermann</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><fpage>1883</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1084/jem.20060336</pub-id><?supplied-pmid 16880258?><pub-id pub-id-type="pmid">16880258</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Lozach</surname><given-names>J</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Pascual</surname><given-names>G</given-names></name><name><surname>Tangirala</surname><given-names>RK</given-names></name><name><surname>Westin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Molecular determinants of crosstalk between nuclear receptors and toll-like receptors</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>707</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.06.029</pub-id><?supplied-pmid 16143103?><pub-id pub-id-type="pmid">16143103</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiyama</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Takano</surname><given-names>K</given-names></name><name><surname>Takano</surname><given-names>Y</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Modulation of glucocorticoid receptor expression, inflammation, and cell apoptosis in septic guinea pig lungs using methylprednisolone</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2008</year><volume>295</volume><fpage>L998</fpage><lpage>L1006</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00459.2007</pub-id><?supplied-pmid 18836031?><pub-id pub-id-type="pmid">18836031</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>PV</given-names></name><name><surname>Pinto</surname><given-names>RA</given-names></name><name><surname>Mamani</surname><given-names>R</given-names></name><name><surname>Uasapud</surname><given-names>PA</given-names></name><name><surname>Bono</surname><given-names>MR</given-names></name><name><surname>Gaggero</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Increased expression of the glucocorticoid receptor &#x003b2; in infants with RSV bronchiolitis</article-title><source>Pediatrics</source><year>2012</year><volume>130</volume><fpage>804</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1542/peds.2012-0160</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haim</surname><given-names>YO</given-names></name><name><surname>Unger</surname><given-names>ND</given-names></name><name><surname>Souroujon</surname><given-names>MC</given-names></name><name><surname>Mittelman</surname><given-names>M</given-names></name><name><surname>Nuemann</surname><given-names>D</given-names></name></person-group><article-title>Resistance of LPS-activated bone marrow derived macrophages to apoptosis mediated by dexamethasone</article-title><source>Sci Rep</source><year>2014</year><volume>10</volume><fpage>4323</fpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Bertol&#x000ed;n</surname><given-names>L</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Fuentes-Prado</surname><given-names>M</given-names></name><name><surname>Roca-Ferrer</surname><given-names>J</given-names></name><name><surname>Alobid</surname><given-names>I</given-names></name><name><surname>Picado</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of lipololysaccharide on glucocorticoid receptor function in control nasal mucosa fibroblasts and in fibroblasts from patients with chronic rhinosinusitis with nasal polyps and asthma</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0125443</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0125443</pub-id><?supplied-pmid 25943109?><pub-id pub-id-type="pmid">25943109</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>NZ</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes</article-title><source>Mol Cell</source><year>2005</year><volume>18</volume><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.03.025</pub-id><?supplied-pmid 15866175?><pub-id pub-id-type="pmid">15866175</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cidlowski</surname><given-names>JA</given-names></name><name><surname>Bellinghan</surname><given-names>DL</given-names></name><name><surname>Powell-Oliver</surname><given-names>FE</given-names></name><name><surname>Lubahn</surname><given-names>DB</given-names></name><name><surname>Sar</surname><given-names>M</given-names></name></person-group><article-title>Novel antipeptide antibodies to the human glucocorticoid receptor: recognition of multiple receptor forms in vitro and distinct localization of cytoplasmic and nuclear recpetors</article-title><source>Mol Endocrinol</source><year>1990</year><volume>4</volume><fpage>1427</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1210/mend-4-10-1427</pub-id><?supplied-pmid 1704480?><pub-id pub-id-type="pmid">1704480</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>The immunopathogenesis of sepsis</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>885</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1038/nature01326</pub-id><?supplied-pmid 12490963?><pub-id pub-id-type="pmid">12490963</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadmiel</surname><given-names>M</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>Glucocorticoid receptor signaling in health and disease</article-title><source>Trends Pharmacol Sci</source><year>2013</year><volume>34</volume><fpage>518</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2013.07.003</pub-id><?supplied-pmid 23953592?><pub-id pub-id-type="pmid">23953592</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Sargent</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name></person-group><article-title>Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages</article-title><source>Clin Exp Immunol</source><year>2009</year><volume>158</volume><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2009.03986.x</pub-id><?supplied-pmid 19737233?><pub-id pub-id-type="pmid">19737233</pub-id></element-citation></ref></ref-list></back></article>